Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Protocols in Neovascular AMD
NCT03552770Phase 4Completed
- Sponsor
- Azienda Ospedaliero-Universitaria di Ferrara
- Start
- Nov 2014
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, randomised, open-label trial of bevacizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Ferrara. Primary endpoints: Best-Corrected Visual Acuity at 12 months, Number of Intra-vitreous Injections of Bevacizumab at 12 months and 2 more. Started Nov 2014; status: completed.
02
Drugs
bevacizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03552770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552770.